Guided Therapeutics, Inc.
GTHP
$0.20
-$0.03-12.28%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 590.00K | 60.00K | 117.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 590.00K | 60.00K | 117.00K | -- |
| Cost of Revenue | -- | 132.00K | 25.00K | 38.00K | -- |
| Gross Profit | -- | 458.00K | 35.00K | 79.00K | -- |
| SG&A Expenses | 474.00K | 1.31M | 384.00K | 709.00K | 340.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -217.00K | -- | -- | -- | -- |
| Total Operating Expenses | 302.00K | 1.57M | 545.00K | 880.00K | 414.00K |
| Operating Income | -302.00K | -980.40K | -485.00K | -763.00K | -414.00K |
| Income Before Tax | -500.00K | -1.22M | -742.00K | -811.00K | -427.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -500.00K | -1.22M | -742.00K | -811.00K | -427.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -500.00K | -1.22M | -742.00K | -811.00K | -427.00K |
| EBIT | -302.00K | -980.40K | -485.00K | -763.00K | -414.00K |
| EBITDA | -300.00K | -977.40K | -483.00K | -760.00K | -412.00K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 88.84M | 84.60M | 81.69M | 78.84M | 68.29M |
| Average Diluted Shares Outstanding | 88.84M | 84.60M | 81.69M | 78.84M | 68.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |